drugset / Trial / NCT01458730
Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
Phase 2
Completed
66 enrolled
University of Aarhus
Mundipharma Pte Ltd. · collabNordic Cancer Union · collabRoche Pharma AG · collabSchering-Plough · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to test the efficacy and tolerability of a multiagent chemotherapy treatment regimen without radiotherapy in patients with newly diagnosed lymphoma in the brain.
Timeline
- Start
- 2007-05
- Primary completion
- 2010-10
- Completion
- 2022-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | DepoCyte | Unknown | — | — |
| Background | HDARAC | Unknown | — | — |
| Background | Ifosfamide | Small molecule | — | — |
| Background | Methotrexate | Small molecule | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |
| Background | Temozolomide | Small molecule | — | — |
| Background | Vincristine | Small molecule | — | — |
| Background | Vindesine | Small molecule | — | — |